A detailed history of Ostrum Asset Management transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Ostrum Asset Management holds 5,273 shares of VRTX stock, worth $2.16 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
5,273
Previous 7,428 29.01%
Holding current value
$2.16 Million
Previous $3.48 Billion 29.56%
% of portfolio
0.2%
Previous 0.3%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$460.0 - $505.78 $991,300 - $1.09 Million
-2,155 Reduced 29.01%
5,273 $2.45 Billion
Q2 2024

Aug 13, 2024

SELL
$392.81 - $485.53 $743,589 - $919,108
-1,893 Reduced 20.31%
7,428 $3.48 Billion
Q1 2024

May 13, 2024

BUY
$407.69 - $446.08 $6,115 - $6,691
15 Added 0.16%
9,321 $3.9 Billion
Q4 2023

Feb 13, 2024

BUY
$343.0 - $410.68 $163,611 - $195,894
477 Added 5.4%
9,306 $3.79 Billion
Q3 2023

Nov 14, 2023

SELL
$338.18 - $362.46 $20,290 - $21,747
-60 Reduced 0.67%
8,829 $3.07 Billion
Q2 2023

Aug 11, 2023

BUY
$314.42 - $351.91 $2,515 - $2,815
8 Added 0.09%
8,889 $3.13 Billion
Q1 2023

May 12, 2023

SELL
$283.23 - $323.1 $1.28 Million - $1.46 Million
-4,524 Reduced 33.75%
8,881 $2.8 Billion
Q3 2020

Nov 12, 2020

BUY
$255.65 - $303.1 $258,206 - $306,131
1,010 Added 8.15%
13,405 $3.65 Million
Q2 2020

Aug 13, 2020

BUY
$225.48 - $295.8 $383,316 - $502,860
1,700 Added 15.9%
12,395 $3.6 Million
Q1 2020

May 14, 2020

BUY
$199.77 - $247.81 $219,747 - $272,591
1,100 Added 11.46%
10,695 $2.55 Million
Q3 2019

Nov 13, 2019

BUY
$166.23 - $187.09 $149,607 - $168,381
900 Added 10.35%
9,595 $1.63 Million
Q2 2019

Aug 13, 2019

BUY
$164.61 - $190.37 $829,963 - $959,845
5,042 Added 138.02%
8,695 $1.59 Million
Q4 2018

Feb 14, 2019

BUY
$151.91 - $192.21 $554,927 - $702,143
3,653 New
3,653 $605,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Ostrum Asset Management Portfolio

Follow Ostrum Asset Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ostrum Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Ostrum Asset Management with notifications on news.